Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide ... demonstrating a 14% reduction in risk of major ...

Researchers randomly assigned patients to receive oral semaglutide gradually titrated to the maximal, 14-mg dose or placebo ... “Delivery of this tablet is more complicated than usual ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide ... therapeutic dosages: 3 ...